Ryan Cook1,2, Brendan Quinn2,3, Keith Heinzerling2, Steve Shoptaw2. 1. Department of Epidemiology, Los Angeles Fielding School of Public Health, University of California, Los Angeles, CA, USA. 2. Departments of Family Medicine and Psychiatry and Biobehavioral Science, Los Angeles David Geffen School of Medicine, University of California, Los Angeles, CA, USA. 3. Centre for Population Health, Burnet Institute, Melbourne, VIC, Australia.
Abstract
BACKGROUND AND AIMS: High rates of loss to follow-up represent a significant challenge to clinical trials of pharmacological treatments for methamphetamine (MA) use disorder. We aimed to estimate and test the relationship between achieving and maintaining abstinence in the initial weeks of study participation and subsequent retention in such trials, hypothesizing that participants able to achieve early abstinence would be less likely to drop out. DESIGN: Data from four randomized controlled trials (RCTs) of pharmacological treatments for MA use disorder were pooled and analyzed using a random-effects approach. SETTING: All trials were conducted in the greater Los Angeles, CA, USA area. PARTICIPANTS: A total of 440 participants were included; trials were conducted between 2004 and 2014. MEASUREMENTS: Participants' ability to achieve a brief period of initial abstinence was measured as the number of MA-negative urine screens completed in the first 2 weeks of the trials. Outcomes were the likelihood of dropout, i.e. missing two consecutive weeks of scheduled urine drug screens, and the number of days participants were retained in the trials. FINDINGS: Study participants achieved an average of three (of six possible) negative urine screens during the first 2 weeks of the trials, 51% dropped out and the average number of days retained was 60 (of 90 maximum). Each additional negative urine screen achieved during the first 2 weeks of the study reduced multiplicatively the odds of dropout by 41% [odds ratio (OR) = 0.59, 95% confidence interval (CI) = 0.53, 0.66]. Abstinence was also a significant predictor of retention time; the hazard ratio for non-completion was 0.75 per additional negative urine screen (95% CI = 0.71, 0.80). CONCLUSIONS: Participants in randomized controlled trials of pharmacological treatments for methamphetamine use disorder who are able to achieve a brief period of early abstinence are retained longer in the trials and are less likely to drop out overall.
RCT Entities:
BACKGROUND AND AIMS: High rates of loss to follow-up represent a significant challenge to clinical trials of pharmacological treatments for methamphetamine (MA) use disorder. We aimed to estimate and test the relationship between achieving and maintaining abstinence in the initial weeks of study participation and subsequent retention in such trials, hypothesizing that participants able to achieve early abstinence would be less likely to drop out. DESIGN: Data from four randomized controlled trials (RCTs) of pharmacological treatments for MA use disorder were pooled and analyzed using a random-effects approach. SETTING: All trials were conducted in the greater Los Angeles, CA, USA area. PARTICIPANTS: A total of 440 participants were included; trials were conducted between 2004 and 2014. MEASUREMENTS: Participants' ability to achieve a brief period of initial abstinence was measured as the number of MA-negative urine screens completed in the first 2 weeks of the trials. Outcomes were the likelihood of dropout, i.e. missing two consecutive weeks of scheduled urine drug screens, and the number of days participants were retained in the trials. FINDINGS: Study participants achieved an average of three (of six possible) negative urine screens during the first 2 weeks of the trials, 51% dropped out and the average number of days retained was 60 (of 90 maximum). Each additional negative urine screen achieved during the first 2 weeks of the study reduced multiplicatively the odds of dropout by 41% [odds ratio (OR) = 0.59, 95% confidence interval (CI) = 0.53, 0.66]. Abstinence was also a significant predictor of retention time; the hazard ratio for non-completion was 0.75 per additional negative urine screen (95% CI = 0.71, 0.80). CONCLUSIONS:Participants in randomized controlled trials of pharmacological treatments for methamphetamine use disorder who are able to achieve a brief period of early abstinence are retained longer in the trials and are less likely to drop out overall.
Authors: Diane Warden; Geetha A Subramaniam; Thomas Carmody; George E Woody; Abu Minhajuddin; Sabrina A Poole; Jennifer Potter; Marc Fishman; Michael Bogenschutz; Ashwin Patkar; Madhukar H Trivedi Journal: Addict Behav Date: 2012-05-08 Impact factor: 3.913
Authors: Matthew Brensilver; Keith G Heinzerling; Aimee-Noelle Swanson; Steven J Shoptaw Journal: Exp Clin Psychopharmacol Date: 2012-08-06 Impact factor: 3.157
Authors: Laura Moreno-López; Natalia Albein-Urios; José Miguel Martinez-Gonzalez; Carles Soriano-Mas; Antonio Verdejo-García Journal: Front Psychiatry Date: 2014-05-20 Impact factor: 4.157
Authors: Steve Shoptaw; Michael J Li; Marjan Javanbakht; Amy Ragsdale; David Goodman-Meza; Pamina M Gorbach Journal: Drug Alcohol Depend Date: 2022-01-19 Impact factor: 4.492
Authors: Andy C Dean; Erika L Nurmi; Scott J Moeller; Nader Amir; Michelle Rozenman; Dara G Ghahremani; Maritza Johnson; Robert Berberyan; Gerhard Hellemann; Ziwei Zhang; Edythe D London Journal: Psychopharmacology (Berl) Date: 2018-11-10 Impact factor: 4.530
Authors: Jone Bjornestad; Thomas Solgaard Svendsen; Tale Ekeroth Slyngstad; Aleksander H Erga; James R McKay; Sverre Nesvåg; Alexander Waagan Skaalevik; Marius Veseth; Christian Moltu Journal: Front Psychiatry Date: 2019-09-18 Impact factor: 4.157